ClinicalTrials.gg
WithdrawnNCT00743847Updated Feb 24, 2009

A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In Subjects With Schizophrenia

A Phase 2 interventional study of placebo and varenicline in Schizophrenia, sponsored by Pfizer. Withdrawn. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2009-02-24.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing varenicline in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. Varenicline · Schizophrenia.

Enrollment
15th of 17
0 · median 24
Started
2009
with 1 other
Phase 2
5 of 17
none open now
Registered
9th of 17
by date
Lead sponsor
1 of 17
Pfizer

Among the 17 studies testing varenicline in Schizophrenia, this one is the 15th largest by enrollment, is one of 2 that started in 2009, is one of 5 in phase 2, and was the 9th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 17 studies testing varenicline in Schizophrenia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing varenicline in Schizophrenia, or all of them as a file.
02

Study summary

The primary objective of this protocol is to assess the efficacy of two dose strengths of varenicline (0.5 mg BID and 1mg BID) as adjunctive treatment for cognitive impairment in symptomatically stable outpatient schizophrenic subjects who are receiving treatment with atypical antipsychotic medications.

A secondary objective is to evaluate the safety and tolerability of two doses of varenicline in symptomatically stable schizophrenic subjects who are receiving treatment with atypical antipsychotic medications.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • schizophrenia, treatment, cognition
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a current diagnosis of schizophrenia
  • Subjects must be on ongoing maintenance antipsychotic monotherapy or combination therapy with risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, or paliperidone.
  • Evidence of stable symptomatology ≥3 months (eg, no hospitalizations for schizophrenia, no increase in level of psychiatric care due to worsening of symptoms of schizophrenia).

Exclusion criteria

Exclusion Criteria:

  • Subjects with a current axis I diagnosis other than schizophrenia.
  • Current treatment with conventional antipsychotics (e.g. fluphenazine, haloperidol) or clozapine, or the use of adjunctive anticholinergic treatment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    placebo

    Drug: placebo

  • Active comparator
    varenicline 0.5 mg BID

    Drug: varenicline

  • Active comparator
    varenicline 1mg BID

    Drug: varenicline

Interventions

  • Drugplacebo

    Subjects randomized to placebo will receive matching placebo and follow the titration schedule and dosing schedule of those randomized to varenicline.

  • Subjects randomized to the 0.5 mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 7 days, then 0.5mg BID for the remainder of the 6 week trial.

    Also known as: Chantix

  • Subjects randomized to the 1mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 3 days, 0.5mg BID x 4 days, then 1mg BID for the remainder of the 6 week trial.

    Also known as: Chantix, Champix

06

What researchers measure

Primary outcomes

  1. CNS Vital Signs Cognition Battery (CNS-VS-M) normed composite score

    Time frame: screening, wk -1, baseline, wk 1,3,6

Secondary outcomes

  1. CNS-VS-M un-normed composite score

    Time frame: screening, wk-1,baseline,wk1,3,6

  2. CNS-VS-M un-normed and normed domain scores

    Time frame: screening, wk-1,baseline, wk1,3,6

  3. University of California San Diego Performance Skills Assessment Brief (UPSA-B) total score

    Time frame: baseline, wk 1,3,6

  4. Severity Item for Cognitive Impairment-Clinician and Patient Versions (SICI-CV; SICI-PV)

    Time frame: baseline, wk6

  5. Global Improvement in Cognition Clinician and Patient Versions (GIC-CV;GIC-PV)

    Time frame: wk 1,3,6

  6. Safety assessments, including adverse events, electrocardiographic assessments, neuropsychiatric assessments (performed weekly), physical exam, and laboratory measures

    Time frame: weekly

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2008
First posted
Aug 29, 2008
Start
Mar 2009
Primary completionEst.
Nov 2009
CompletionEst.
Nov 2009
Last update
Feb 24, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00743847
Lead sponsor
Pfizer
First posted
Aug 29, 2008
Start date
Mar 2009
Primary completion
Nov 2009 (estimated)
Completion
Nov 2009 (estimated)
Last update
Feb 24, 2009

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion